Hualan Vac(SZ:301207)2025-01-16 07:55Financial Performance - The company expects a net profit for 2024 to be between 200 million and 250 million CNY, representing a decline of 70.93% to 76.74% compared to the previous year's profit of 859.9686 million CNY [3]. - The net profit after deducting non-recurring gains and losses is projected to be between 110 million and 160 million CNY, down 78.89% to 85.49% from last year's 757.9972 million CNY [3]. - Non-recurring gains and losses are expected to impact net profit by approximately 90 million CNY, primarily from investment income generated from idle funds [6]. Market and Sales Impact - The business development and profitability have been significantly impacted by changes in vaccination rates, declining market demand, and reduced sales [6]. - The company adjusted the price of its quadrivalent influenza vaccine by over 40% in June 2024 to enhance market competitiveness and accessibility [5]. Research and Development - The company maintains a high level of investment in R&D for innovative vaccines and gene-engineered vaccines, which has negatively affected net profit [6].